Search Results

Applied DNA Sciences, Inc., a leader in PCR-based DNA technologies, will showcase its Linea™ IVT and Linea™ DNA platforms at the 24th Annual World Vaccine Congress, which will be held April 1 - 4, 2024.

Applied DNA Sciences, Inc. announced the expansion of its Linea IVT platform (the to include the manufacture of self-amplifying mRNA (“saRNA”).

Applied DNA Sciences, Inc. (NASDAQ:APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced the general availability of Linea™ IVT platform evaluation kits (the “Kit”) and the first shipment of a Kit to an existing Linea™ IVT Template customer.

Applied DNA Sciences, Inc. announced today that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent application 18/302,247, entitled “Compositions and Methods for RNA Synthesis.”

Applied DNA Sciences, Inc. and Kudo Biotechnology announced their entry into a joint development agreement to integrate Applied DNA’s Linea™ IVT platform into Kudo Bio’s commercial mRNA manufacturing workflows.

Applied DNA Sciences, Inc., a leader in PCR-based DNA technologies, and Alphazyme LLC, a Maravai LifeSciences company and global provider of specialty enzymes used in the life sciences sector, announced the successful conclusion of the companies’ previously announced Linea™ RNAP manufacturing scale-up agreement.

Lucid Diagnostics Inc. a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc., announced the peer-reviewed publication of positive data from a National Cancer Institute -sponsored, prospective, multicenter clinical validation study assessing the performance of Lucid’s EsoGuard® Esophageal DNA Test on samples collected with its EsoCheck® Esophageal Cell Collection Device.

Eurofins Genomics Blue Heron is thrilled to announce the launch of our cutting-edge IVT mRNA Synthesis Service.